Treatment satisfaction with calcitonin gene-related peptide monoclonal antibodies as a new patient-reported outcome measure: A real-life experience in migraine.

Background: To evaluate treatment satisfaction with galcanezumab as a patient-reported outcome measure (PROM) in migraine.

Methods: Patients with ≥8 headache days/month that had failed at ≥3 medications were included. Demographic and medical history were collected.